Aug 13, 2025 12:00
KLRS - Kalaris Therapeutics, Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 6.91 0.01 (0.22%) | -0.02 (-0.22%) | 0.05 (0.73%) | 0.07 (1.02%) | --- | 0.01 (0.22%) | 0.0 (0.0%) | 0.0 (0.0%) |
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Market Period:
Market
Earnings & Ratios
- Basic EPS:
- -2.52
- Diluted EPS:
- -2.52
- Basic P/E:
- -2.748
- Diluted P/E:
- -2.748
- RSI(14) 1m:
- 40.54
- VWAP:
- 6.94
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|